buyModerate

Anand Mehra bought $1.5M of ACRS

director at Aclaris Therapeutics, Inc.. 666,666 shares at an average of $2.25, traded Nov 19, 2024, filed Nov 20, 2024.

Conviction score

Value

$1.5M

666,666 shares

Holdings after

710,030

+1537% from before

From 52-week low

no price yet

From 52-week high

no price yet

Score components

Role
Director
+15
Trade size
$1.5M at market
+25
Relative to holdings
Holdings up 1537%
+10
Price context
No price history yet
0
Cluster
No other insider buying within 14 days
0
Repeat buying
First buy in 90 days
0
Track record
Too few past buys to judge (0 with prices)
0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -31.3%, 3m -41.7%, 6m -67.4%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ACRSOct 9, 2026 · close 3.83

Since filing Nov 20, 2024: -3.3%SPY +34.9% · excess -38.2%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001415889-24-027348, as filed. Open on EDGAR

Date	Transaction	Shares	Price	Value	Holdings after	Filed
Nov 19, 2024	POpen-market purchase Common Stock	+666,666	$2.25	$1.5M	710,030	Nov 20, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.